JP2006514051A - 慢性心不全の治療 - Google Patents

慢性心不全の治療 Download PDF

Info

Publication number
JP2006514051A
JP2006514051A JP2004565376A JP2004565376A JP2006514051A JP 2006514051 A JP2006514051 A JP 2006514051A JP 2004565376 A JP2004565376 A JP 2004565376A JP 2004565376 A JP2004565376 A JP 2004565376A JP 2006514051 A JP2006514051 A JP 2006514051A
Authority
JP
Japan
Prior art keywords
group
alkyl
chf
unsubstituted
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004565376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514051A5 (cg-RX-API-DMAC7.html
Inventor
チヤオ,リン
Original Assignee
タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド filed Critical タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド
Publication of JP2006514051A publication Critical patent/JP2006514051A/ja
Publication of JP2006514051A5 publication Critical patent/JP2006514051A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2004565376A 2002-12-20 2003-12-11 慢性心不全の治療 Pending JP2006514051A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/325,420 US20040122067A1 (en) 2002-12-20 2002-12-20 Treatment of chronic heart failure
PCT/US2003/039410 WO2004060489A2 (en) 2002-12-20 2003-12-11 Treatment of chronic heart failure

Publications (2)

Publication Number Publication Date
JP2006514051A true JP2006514051A (ja) 2006-04-27
JP2006514051A5 JP2006514051A5 (cg-RX-API-DMAC7.html) 2007-02-01

Family

ID=32593758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004565376A Pending JP2006514051A (ja) 2002-12-20 2003-12-11 慢性心不全の治療

Country Status (7)

Country Link
US (1) US20040122067A1 (cg-RX-API-DMAC7.html)
EP (1) EP1581308A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006514051A (cg-RX-API-DMAC7.html)
CA (1) CA2506719A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006628A (cg-RX-API-DMAC7.html)
PL (1) PL375893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004060489A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016017826A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬
WO2016133069A1 (ja) * 2015-02-17 2016-08-25 株式会社 三和化学研究所 心不全の予防又は治療のための医薬

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
WO2006121995A2 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
GB0909243D0 (en) * 2009-05-29 2009-07-15 Univ Dundee Angina treatment
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (fr) * 1990-11-30 1992-06-11 Teijin Limited Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
JP2002527378A (ja) * 1998-10-15 2002-08-27 インペリアル・カレッジ・イノベイションズ・リミテッド 治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1520699A (en) * 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
CZ297264B6 (cs) * 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
EP1212064A2 (en) * 1999-03-09 2002-06-12 Max-Delbrück-Centrum Für Molekulare Medizin Use of inhibitors of endotoxin for the treatment of heart failure and of cachexia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (fr) * 1990-11-30 1992-06-11 Teijin Limited Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
JP2002527378A (ja) * 1998-10-15 2002-08-27 インペリアル・カレッジ・イノベイションズ・リミテッド 治療方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016017826A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬
JPWO2016017826A1 (ja) * 2014-07-30 2017-04-27 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬
US10301300B2 (en) 2014-07-30 2019-05-28 Teijin Limited Xanthine oxidase inhibitor
WO2016133069A1 (ja) * 2015-02-17 2016-08-25 株式会社 三和化学研究所 心不全の予防又は治療のための医薬

Also Published As

Publication number Publication date
MXPA05006628A (es) 2005-09-30
WO2004060489A3 (en) 2004-11-25
EP1581308A2 (en) 2005-10-05
CA2506719A1 (en) 2004-07-22
PL375893A1 (en) 2005-12-12
WO2004060489A2 (en) 2004-07-22
US20040122067A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
US7087632B2 (en) Benzimidazole derivatives as therapeutic agents
EP1988776B1 (en) Antiviral drugs for treatment of arenavirus infection
AU2006327892B2 (en) Histone deacetylase inhibitors for enhancing activity of antifungal agents
KR101585584B1 (ko) 아레나바이러스 감염을 치료하기 위한 항바이러스 약물
MX2009007680A (es) Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios.
US20040122067A1 (en) Treatment of chronic heart failure
FR2962649A1 (fr) Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
EA014425B1 (ru) Терапевтические соединения
JP2013151518A (ja) 腎結石症を治療する方法
EP2887804A1 (en) Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use
KR20210023984A (ko) 헤테로환형 고리 및 아미노기로 치환된 피리딘 유도체
US20150133477A1 (en) Methods for Reducing Uric Acid Levels Using Barbiturate Derivatives
WO2008061647A1 (en) Use of a compound as vegf inhibitor
US11155552B2 (en) Rutaecarpine analogs and applications thereof
JP2007529545A (ja) ダウン症候群の治療法
US20090005404A1 (en) Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
US20040254228A1 (en) Treatment of chronic heart failure
US20110269708A1 (en) P2x7 antagonists to treat affective disorders
JP4525964B2 (ja) 肺高血圧症予防治療剤
KR20090117703A (ko) 알리스키렌 및 아보센탄을 이용한 의약 조성물
EP1517687B1 (de) Arzneimittel zur behandlung des "systemic inflammatory response syndrome"
US20120046331A1 (en) Antifungal Agents and Uses Thereof
WO2026064493A1 (en) Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure
WO2012057343A1 (ja) Nad(p)hオキシダーゼ阻害剤、酸化ストレス疾患治療薬、酸化ストレス疾患治療方法及びスクリーニング方法
EP4593827A2 (en) Vanoxerine for use in the treatment of brain cancer, breast cancer, pancreatic cancer and lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810